Insomnia Severity Index (ISI)

1. Abstract

The Insomnia Severity Index (ISI) is a brief, highly reliable, and empirically validated self-report assessment instrument designed to evaluate the subjective nature, clinical severity, and daytime impact of insomnia in adult and clinical populations. Developed primarily by Charles M. Morin in 1993, the instrument was conceived to align directly with the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV and DSM-5) and the International Classification of Sleep Disorders (ICSD). The ISI comprises 7 items assessing the severity of sleep onset latency, sleep maintenance difficulties, early morning awakening problems, subjective satisfaction with current sleep patterns, perceived interference with daily functioning, noticeability of impairment to others, and the overall distress or worry provoked by sleep disturbance.

Each item is rated on a 5-point Likert scale ranging from 0 to 4, yielding a total score between 0 and 28. Standardized clinical cutoffs categorize scores into four tiers: absence of clinically significant insomnia (0–7), subthreshold insomnia (8–14), clinical insomnia of moderate severity (15–21), and severe clinical insomnia (22–28). Across diverse clinical trials and epidemiological cohorts, the ISI demonstrates robust psychometric integrity. Internal consistency routinely exhibits Cronbach’s alpha coefficients exceeding .88 to .91, with strong test-retest reliability across 1- to 4-week testing intervals. Exploratory and confirmatory factor analyses typically substantiate a robust unidimensional model, though empirical evidence in specialized psychiatric and medical subsets often supports a two-factor or three-factor structure delineating nocturnal symptoms, sleep dissatisfaction, and daytime consequences. Due to its sensitivity to therapeutic changes, the ISI is recognized globally as a gold-standard primary and secondary outcome measure in clinical trials evaluating Cognitive Behavioral Therapy for Insomnia (CBT-I) and pharmacological pharmacotherapies.

2. Keywords

Insomnia Severity Index, ISI, insomnia assessment, sleep disorders, Cognitive Behavioral Therapy for Insomnia, CBT-I, psychometrics, sleep diary, sleep quality, self-report measurement, daytime impairment

3. Authors

The primary author and principal architect of the Insomnia Severity Index is Charles M. Morin, Ph.D., Professor of Psychology and Director of the Sleep Research Centre (Centre de recherche CERVO) at Université Laval in Quebec City, Canada. Dr. Morin is an internationally renowned authority on behavioral sleep medicine, insomnia pathophysiology, and non-pharmacological interventions for sleep disorders.

Key collaborators involved in the formal validation, psychometric refinement, and clinical translation of the instrument include:

• Geneviève Belleville, Ph.D. — Université Laval, Quebec City, Canada.
• Lynda Bélanger, Ph.D. — Université Laval, Quebec City, Canada.
• Hans Ivers, Ph.D. — Université Laval, Quebec City, Canada.
• Colin A. Espie, Ph.D., D.Sc. — University of Oxford, Department of Clinical Neurosciences, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom.
• Ruth M. Benca, M.D., Ph.D. — Wake Forest School of Medicine, Winston-Salem, North Carolina, United States.

Institutional contact and academic correspondence regarding the original psychometric manual are maintained through the Department of Psychology, Pavillon Félix-Antoine-Savard, Université Laval, Quebec City, QC, G1V 0A6, Canada.

4. Purpose

The primary clinical and psychometric purpose of the Insomnia Severity Index (ISI) is to provide a brief, cost-effective, and standardized self-report metric assessing the nature, global severity, and multidimensional impact of insomnia. In routine medical, psychiatric, and sleep medicine settings, insomnia is frequently obscured or conflated with comorbid psychiatric conditions such as major depressive disorder, generalized anxiety disorder, and chronic pain syndromes. The ISI addresses this diagnostic challenge by standardizing subjective sleep complaints over a recall period of the preceding two weeks or month, allowing clinicians to screen rapidly for clinical-level pathology.

From an applied clinical perspective, the ISI fulfills three pivotal functions:

1. Diagnostic Screening: Identifying individuals who meet subjective criteria for chronic or episodic insomnia disorder as outlined in standard classification systems (e.g., DSM-5-TR, ICSD-3).
2. Treatment Planning and Triage: Providing detailed insight into whether a patient’s sleep pathology is dominated by nocturnal initiation deficits, mid-nocturnal maintenance awakenings, terminal wakefulness, or pronounced cognitive distress and functional interference.
3. Treatment Outcome Monitoring: Serving as a highly sensitive instrument capable of detecting minimal clinically important differences (MCID). A reduction of 6 or more points on the ISI is widely accepted across clinical trial literature as denoting meaningful clinical improvement, whereas post-treatment scores below 8 typically define complete clinical remission.

In clinical trials, particularly those investigating Cognitive Behavioral Therapy for Insomnia (CBT-I) and hypnotic pharmacotherapies, the ISI functions as a premier endpoint metric. Unlike objective sleep metrics like polysomnography (PSG) or wrist actigraphy, which capture physiological parameters such as sleep architecture, total sleep time (TST), and sleep onset latency (SOL), the ISI systematically captures the patient’s subjective suffering and secondary functional decrements. This subjective appraisal is critical, as clinical definitions of insomnia fundamentally hinge upon subjective distress and perceived daytime impairment rather than absolute minutes of physiological slumber.

5. Psychological Construct

The Insomnia Severity Index operationalizes insomnia as a multifaceted, biopsychosocial condition characterized not only by quantitative nocturnal disruptions but also by qualitative cognitive evaluations, emotional distress, and perceived daytime functional impairments. The scale encompasses several discrete yet interconnected dimensions:

Nocturnal Sleep Disruption (Items 1a, 1b, 1c)

This sub-dimension captures the classic nocturnal presentation of insomnia, reflecting distinct circadian and homeostatic sleep architecture failures:

• Difficulty Falling Asleep (Sleep-Onset Insomnia): Assesses prolonged sleep latency, often driven by cognitive hyperarousal, pre-sleep rumination, or elevated autonomic arousal upon entering bed.
• Difficulty Staying Asleep (Sleep-Maintenance Insomnia): Evaluates mid-nocturnal awakenings and fragmentation of sleep architecture, capturing difficulties returning to sleep after waking in the middle of the night.
• Problems Waking Up Too Early (Terminal Insomnia): Assesses early morning awakenings occurring significantly before the desired wake time, with complete inability to resume sleep, a clinical hallmark frequently correlated with affective dysregulation and neuroendocrine shifts.

Subjective Sleep Appraisal (Item 2)

This dimension measures the respondent’s overarching cognitive evaluation of and emotional satisfaction with their current sleep patterns. It dissociates raw sleep quantity from perceived sleep quality. Many patients display normal objective sleep parameters via PSG but manifest profound sleep state misperception (paradoxical insomnia); this item captures that affective-cognitive mismatch.

Perceived Daytime Functional Interference (Item 3)

Insomnia is defined clinically by its daytime consequences. This construct assesses the degree to which non-restorative or fragmented sleep degrades neurocognitive, occupational, and interpersonal faculties. Areas evaluated include daytime fatigue, psychomotor slowness, affective lability, occupational absenteeism or presenteeism, compromised memory retention, and executive dysfunction.

Noticeability of Impairment (Item 4)

This dimension addresses the social and interpersonal perception of sleep-related disability. Patients evaluate how observable their fatigue, mood changes, and reduced operational capacity are to peers, family, and colleagues. In clinical psychology, this reflects social anxiety, fear of negative evaluation, and the perceived breakdown of behavioral compensation strategies.

Distress and Worry (Item 5)

This dimension operationalizes the affective burden and anxiety specifically focused on the sleep problem. It evaluates cognitive catastrophic misinterpretations (e.g., "If I don’t sleep tonight, I will fail tomorrow"), chronic worry, and the emotional toll of unpredictability regarding sleep performance, which often sustains chronic sleep disturbance.

6. Theoretical Framework

The theoretical architecture of the Insomnia Severity Index is firmly rooted in cognitive-behavioral paradigms of insomnia, particularly the Spielman 3-P Model (Spielman et al., 1987), the Cognitive Model of Insomnia formulated by Allison G. Harvey (2002), and Charles M. Morin’s Integrative Cognitive-Behavioral Model (1993).

The Spielman 3-P Model

The 3-P model posits that chronic insomnia evolves through three consecutive influences:

• Predisposing Factors: Biological traits (e.g., hyperarousal tendencies, genetic vulnerabilities) and psychological traits (e.g., perfectionism, trait anxiety).
• Precipitating Events: Acute biological, environmental, or psychological stressors (e.g., bereavement, medical illness, occupational changes) triggering initial sleep disturbances.
• Perpetuating Mechanisms: Maladaptive behavioral practices (e.g., spending excessive time in bed, irregular wake times, daytime napping) and cognitive distortions that sustain sleep disruption long after the acute precipitant has resolved.

The ISI specifically operationalizes these perpetuating factors. Items assessing worry, noticeability, and daytime interference directly capture the cognitive hyperarousal and maladaptive appraisal processes that perpetuate sleep difficulty night after night.

Harvey’s Cognitive Model of Insomnia

Harvey’s model emphasizes that chronic insomnia is maintained by a cascade of cognitive processes operating across daytime and nocturnal periods. Catastrophic worry about sleep loss leads to autonomic hyperarousal and emotional distress. This triggers selective attention and monitoring for sleep-related internal threats (e.g., bodily sensations of fatigue, heart rate) and external cues, resulting in distorted perceptions of sleep deficit.

Items 4, 5, and 6 of the ISI map directly onto Harvey’s cognitive domains: they assess the attentional focus on daytime deficits, interpersonal hyper-awareness (noticeability), and negative cognitive ruminations regarding the long-term consequences of insomnia.

Morin’s Integrative Behavioral-Cognitive Formulation

Morin posits an interactive feedback loop linking four interrelated domains: hyperarousal (emotional, cognitive, and physiological), dysfunctional sleep cognitions, maladaptive sleep habits, and the consequences of insomnia. As depicted in this framework, distress regarding sleep impairment reinforces somatic arousal during the pre-sleep interval, which in turn lengthens sleep latency. The ISI was explicitly engineered to serve as an outcome measure capable of detecting shifts across every node of this loop.

7. Validity

The psychometric validity of the Insomnia Severity Index has been established across clinical, psychiatric, and community populations in dozens of languages.

Construct and Structural Validity

Construct validity is evidenced by the scale’s alignment with clinical diagnostic frameworks. In a landmark validation study by Bastien, Vallières, and Morin (2001), the ISI demonstrated excellent discriminant capacity, cleanly distinguishing primary insomniacs from healthy controls. Receiver Operating Characteristic (ROC) analyses by Morin, Belleville, Bélanger, and Ivers (2011) confirmed that an ISI total score of 10 yielded optimal sensitivity (86.1%) and specificity (87.7%) for detecting insomnia cases in population-based samples, whereas a cutoff score of 14 yielded optimal parameters (82.4% sensitivity, 82.2% specificity) within specialized clinical sleep centers.

Convergent Validity

Convergent validity has been repeatedly demonstrated through significant correlations with other validated subjective sleep instruments and psychological inventories:

• Pittsburgh Sleep Quality Index (PSQI): Correlations between the ISI and the PSQI typically range from r = .74 to .84 (p < .001), indicating strong construct overlap while maintaining distinct operational goals (the PSQI measuring broader sleep hygiene and quality, the ISI focusing strictly on insomnia severity).
• Sleep Diaries: Significant moderate-to-strong correlations are found between ISI scores and daily consensus sleep diary metrics, including Sleep Onset Latency (SOL; r = .35 to .55), Wake After Sleep Onset (WASO; r = .38 to .60), and Sleep Efficiency percentage (SE%; r = -.45 to -.65).
• Psychological Distress Measures: The ISI correlates robustly with measures of depression and anxiety, including the Beck Depression Inventory (BDI-II; r = .50 to .65) and the Beck Anxiety Inventory (BAI; r = .40 to .58).

Discriminant and Known-Groups Validity

The ISI clearly differentiates clinical insomnia from other sleep pathologies such as obstructive sleep apnea (OSA), restless legs syndrome (RLS), and circadian rhythm sleep disorders. While patients with OSA frequently score moderately high on the PSQI due to general sleep disruption, their ISI distress and worry items remain significantly lower than those observed in patients with primary chronic insomnia. Additionally, the ISI distinguishes clinical responders from non-responders in randomized controlled trials of CBT-I.

8. Reliability

The reliability of the Insomnia Severity Index has been verified using classical test theory and item response theory models.

Internal Consistency

Across diverse clinical and non-clinical cohorts, the ISI demonstrates high internal consistency:

• In the original validation study by Bastien et al. (2001), the internal consistency coefficient was Cronbach’s α = .74 in a community cohort and α = .78 in a clinical sample.
• Subsequent large-scale validation studies (Morin et al., 2011) utilizing larger sample sizes (N > 1,600) reported higher internal consistency estimates of α = .90 to .91.
• Item-total correlations for each of the 7 items routinely fall between .55 and .78, indicating that all questions contribute substantially to the unified construct without redundant collinearity.

Test-Retest Reliability

Temporal stability is high when testing stable, untreated individuals with chronic insomnia:

• Over a 2- to 4-week test-retest interval without therapeutic intervention, intra-class correlation coefficients (ICC) range from r = .78 to .89.
• Item-level test-retest reliability ranges from r = .68 to .81, confirming that patient self-appraisal of both nocturnal and daytime components remains steady across time in the absence of clinical treatment.

9. Factor Analysis

The latent structural integrity of the ISI has been investigated via exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) across numerous cultural and diagnostic samples, yielding either unidimensional, two-factor, or three-factor solutions.

Unidimensional Structure

When evaluated in primary care screening environments or general population cohorts, CFA analyses frequently support a parsimonious single-factor model where all 7 items load heavily onto a general "Insomnia Severity" construct. In these models, standardized factor loadings consistently range from .60 to .85, with adequate fit indices: Comparative Fit Index (CFI) > .95, Tucker-Lewis Index (TLI) > .93, and Root Mean Square Error of Approximation (RMSEA) < .06.

Three-Factor Latent Structure

In clinical sleep research and specialized psychiatric cohorts, a three-factor oblique model often yields superior empirical fit:

• Factor 1: Nocturnal Sleep Difficulties — Comprising Items 1a (sleep onset), 1b (sleep maintenance), and 1c (early morning awakening). Factor loadings range between .68 and .88.
• Factor 2: Sleep Dissatisfaction — Comprising Item 2 (satisfaction with current sleep pattern), occasionally loading alongside distress markers. Standardized loadings range between .72 and .84.
• Factor 3: Daytime Impact and Worry — Comprising Items 3 (interference), 4 (noticeability), and 5 (distress/worry). Factor loadings range between .62 and .89.

This three-factor model demonstrates excellent fit indices across multiple investigations (e.g., χ²/df < 2.5, CFI = .98, TLI = .97, RMSEA = .045, Standardized Root Mean Square Residual [SRMR] = .032), reflecting the distinct theoretical divergence between night-time symptom presentation and secondary daytime consequences.

10. Instrument / Measurement Tool

• Instrument Name: Insomnia Severity Index (ISI)
• Primary Author: Charles M. Morin, Ph.D. (1993)
• Instrument Type: Self-report psychometric questionnaire
• Administration Format: Paper-and-pencil, computer-based, or clinician-administered interview
• Completion Time: Approximately 3 to 5 minutes
• Target Population: Adults and adolescents aged 12 years and older
• Recall Period: Past two weeks (standard) or past month
• Number of Items: 7 items (Item 1 is subdivided into 1a, 1b, 1c)
• Response Format: 5-point Likert scale (0 to 4). For items 1a-1c: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very severe. For item 2: 0 = Very satisfied, 1 = Satisfied, 2 = Moderately satisfied, 3 = Dissatisfied, 4 = Very dissatisfied. For item 3: 0 = Not at all interfering, 1 = A little, 2 = Somewhat, 3 = Much, 4 = Very much interfering. For item 4: 0 = Not at all noticeable, 1 = A little, 2 = Somewhat, 3 = Much, 4 = Very much noticeable. For item 5: 0 = Not at all worried, 1 = A little, 2 = Somewhat, 3 = Much, 4 = Very much worried.
• Scoring Method: All 7 items are summed directly to produce a global composite score ranging from 0 to 28. No items are reverse-scored.
• Clinical Interpretive Ranges:
  • 0 – 7: No clinically significant insomnia
  • 8 – 14: Subthreshold (mild) insomnia
  • 15 – 21: Clinical insomnia (moderate severity)
  • 22 – 28: Clinical insomnia (severe)

11. Permissions & Fee and Test Year

The Insomnia Severity Index was first published in 1993 by Dr. Charles M. Morin in his academic monograph, Insomnia: Psychological Assessment and Management (Guilford Press). Dr. Morin and his academic affiliates hold the intellectual property and copyright to the scale.

For non-commercial research, academic inquiry, and routine individual clinical practice, the ISI is widely made available without licensing fees, provided the scale is unmodified and proper bibliographic attribution is provided. However, commercial use, pharmaceutical clinical trials, integration into commercial digital health tools, or sponsored medical research typically requires formal licensing agreements and royalty fee structures administered through Dr. Morin’s office at Université Laval or commercial distribution agencies (such as Mapi Research Trust / PROQOLID). Researchers must verify terms with copyright holders prior to commercial digital deployment.

12. References

• Bastien, C. H., Vallières, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine, 2(4), 297–307. https://doi.org/10.1016/S1389-9457(00)00065-4
• Harvey, A. G. (2002). A cognitive model of insomnia. Behaviour Research and Therapy, 40(8), 869–893. https://doi.org/10.1016/S0005-7967(01)00061-4
• Morin, C. M. (1993). Insomnia: Psychological assessment and management. Guilford Press.
• Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep, 34(5), 601–608. https://doi.org/10.1093/sleep/34.5.601
• Spielman, A. J., Caruso, L. S., & Glovinsky, P. B. (1987). A behavioral perspective on insomnia treatment. Psychiatric Clinics of North America, 10(4), 541–553. https://doi.org/10.1016/S0193-953X(18)30532-X

13. Items of the Scale (Questionnaire)